Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroblastoma 2Meningioma 2Medulloblastoma 2Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 18Etoposide 12Cisplatin 11Temozolomide 10Vincristine 9Radiotherapy 9Magnetic Resonance Spectroscopy 9Filgrastim 8Irinotecan 7Carboplatin 7X-Rays 6Phantoms, Imaging 6Topotecan 5Specimen Handling 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Thiotepa 4Radiation 4Lomustine 4Biopsy 4Bevacizumab 4tipifarnib 3sargramostim 3palbociclib 3Methotrexate 3HhAntag691 3Chemotherapy, Adjuvant 3ulixertinib 2tazemetostat 2sonidegib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Medulloblastoma × arginyllysine × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡